KROS
Keros Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -10.0% ·
share flow -16.0% ·
net new positions -11.1%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 68 | -2 | 12.51M | $133.89M | +5 | −7 |
| Q1 2026 | 72 | +4 | 12.53M | $138.59M | +8 | −4 |
| Q4 2025 | 68 | +1 | 14.80M | $301.38M | +1 | — |
| Q3 2025 | 16 | 0 | 12.05M | $190.67M | — | — |
| Q2 2025 | 13 | +1 | 9.42M | $125.76M | +2 | −1 |
| Q1 2025 | 9 | -1 | 3.92M | $39.99M | +1 | −2 |
| Q4 2024 | 10 | 0 | 4.67M | $74.00M | +1 | −1 |
| Q3 2024 | 9 | -1 | 4.72M | $274.14M | +1 | −2 |
| Q2 2024 | 10 | — | 3.52M | $160.87M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 1.30M | +8.2% | $13.27M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | D. E. Shaw & Co. ✦ | 1.26M | +10340.0% | $12.87M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 806.18K | +5.3% | $8.22M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 806.18K | +5.3% | $8.22M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Millennium Management ✦ | 233.20K | -73.4% | $2.38M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 191.61K | -75.8% | $1.95M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 191.61K | -75.8% | $1.95M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 62.37K | +85.3% | $635,571 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | T. Rowe Price ✦ | 43.23K | -95.2% | $441,000 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 22.14K | New | $225,565 | 0.0% | New | 1 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 22.14K | New | $225,565 | 0.0% | New | 1 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 22.14K | New | $225,565 | 0.0% | New | 1 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 22.14K | New | $225,565 | 0.0% | New | 1 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 22.14K | New | $225,565 | 0.0% | New | 1 | SEC ↗ |
| 15 | Point72 Asset Management ✦ | 6 | -99.6% | $59 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| AQR Capital Management | $225,565 | 0.0% |
| AQR Capital Management | $225,565 | 0.0% |
| AQR Capital Management | $225,565 | 0.0% |
| AQR Capital Management | $225,565 | 0.0% |
| AQR Capital Management | $225,565 | 0.0% |
Exited
| Norges Bank | $1.03M | was 0.0% |
| Wellington Management | $222,143 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 149 holders, 18.56M shares, $201.20M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 1.00K sh @ 10.27 · $10,270
Open-market sales (S)
Officer · 4.49K sh · $46,151
Director · 551 sh · $5,675
Officer · 3.57K sh · $36,715
Officer · 1.22K sh · $12,595
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology